Tissue-specific genes are believed to be good drug targets due to improved safety. 26 Here we show that this intuitive notion is not reflected in phase 1 and 2 clinical trials, 27 despite the historic success of tissue-specific targets and their 2.3-fold 28 overrepresentation among targets of marketed non-oncology drugs. We compare 29 properties of tissue-specific genes and drug targets. We show that tissue-specificity of 30 the target may also be related to efficacy of the drug. The relationship may be indirect 31 (enrichment in Mendelian disease genes) or direct (elevated ability to spread 32 perturbations in human protein-protein interactome for tissue-specifically produced 33 enzymes and secreted proteins). Reduced evolutionary conservation of tissue-specific 34 genes may represent a bottleneck for drug projects, prompting development of novel 35 models with smaller evolutionary gap to humans. We highlight numerous open 36 opportunities to use tissue-specific genes in drug research and hope that the current 37 study will facilitate discovery efforts. 38 39 40 41 42 43 44 45 46 47 48 65 (2018) 14 . Thus, systematic studies showing a significant overrepresentation of tissue-66 specific genes among drug targets and comprehensive resources have been available 67 since 2008. The average time from a lead compound to entering phase 1 clinical trial 68 is 31.2 months 15 . Let's assume that validation of the biological hypothesis and 69 identification of a lead compound take an equally long time. Then, ten years are 70 sufficient for the findings of basic research to find reflection in early phase clinical trials. 71 Now is good time to test if the industry took advantage of omics studies and pursued 72 tissue-specific targets or not. 73 4 In this study, we examine the prevalence of tissue-specific genes among targets of 74 marketed drugs and drugs in clinical trials. We also investigate properties of tissue-75 specific genes compared to drug targets. Why are these questions important to 76 address? If tissue-specific targets are not actively pursued in early clinical trials, such 77 study would raise awareness of open opportunities. Opportunities to discover new 78 targets are not exhausted. A recent study by Oprea et al. indicates that only 3% of 79 human proteins are targeted by marketed or clinical trial drugs ("Tclin") whereas 35% 80 have an unknown biological function and are not actively studied ("Tdark") 16 . Also, an 81 important parallel exists between tissue-specific genes and targets of marketed drugs. 82 As first demonstrated in 2004, tissue-specific genes are enriched in Mendelian 83 disorder genes 17 . The enrichment was confirmed by Yang et al. in 2016 9 . 53% targets 84 of marketed drugs are implicated in Mendelian disorders 18 . Drugs targeting genes with 85 a genetic link to human disease are less likely to fail in clinical trials due to lack of 86 efficacy 19 . Thus, there may be a relationship between tissue-specificity of the target 87 and efficacy of the drug. In fact, a recent study by Rouillard, Hurle and Agarwal 88 concentrated on identification of omics features distinguishing targets that succeeded 89 and failed in phase 3 trials for non-oncology diseases 20 . Phase 3 trial failures were 90 enriched in failures due to lack of efficacy. Rouillard and colleagues limited their 91
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Narrow expression in one or a few tissues is considered desirable for drug targets due 50 to reduced risk of side effects 1,2 . Genes with narrow expression are often called 'tissue-51 specific' or 'tissue-enriched'. Studies on microarray 3-5 and a combination of sequencing and proteomics data 6, 7 confirm that targets of marketed drugs are biased 53 towards tissue-specific genes. To the best of our knowledge, the first quantitative 54 estimate was published in 2008. Dezso et al. demonstrated that tissue-specific genes 55 are twice more likely to become drug targets than broadly expressed house-keeping 56 genes 8 . Yang et al. confirmed a 1.7-fold higher likelihood in 2016 9 . Dezso et al. 57 observed that tissue-specific genes may represent attractive drug targets due to their 58 role in tissue biology and disease (e.g., brain-specific GABRB2, a receptor for the 59 inhibitory neuromediator gamma-aminobutyric acid, is a target of sedative agents) 8 . 60 These studies assessed tissue-specificity in healthy tissues. Their findings also 61 extrapolate to diseased tissues because targets of marketed and phase 3 drugs are 62 expressed in disease-relevant tissues even in the healthy state in 87% of the cases 10 . 63 Also, substantial efforts are dedicated to cataloguing tissue-specific genes such as 64 databases TiGER (2008) 11 , TiSGeD (2010) 12 , VeryGene (2011) 13 and TissGDB 2*10 -6 ). Targets of withdrawn drugs were also enriched in tissue-specific genes at x = 148 8 to 10. The reason for withdrawal from the market was toxicity with few exceptions 149 like unintended use for self-poisoning (barbiturates) and lack of efficacy (drotrecogin 150 alpha). Targets of withdrawn drugs had 95% overlap (57 of 60) with targets of 151 marketed drugs. Hence, withdrawal of these drugs from the market could not be 152 uniquely attributed to their mechanism-of-action targets. For example, cholinergic 153 nicotinic receptors CHRNA1, CHRND and CHRNG are targets of curare-like 154 neuromuscular blocking agents. Rapacuronium bromide was withdrawn from the 155 market due to adverse events while other drugs like vecuronium continue to be used. 156 We used x = 6 to define tissue-specificity in all subsequent analyses, because the 157 enrichment in tissue-specific genes among targets of marketed drugs became 158 significant at this constraint. 159 The overlap between targets of withdrawn and marketed drugs motivated us to 160 examine 'recycling' of drug targets. Target genes can re-enter clinical trials when new 161 drugs are developed for the same (e.g., generations of H2 histamine receptor HRH2 162 blockers as anti-ulcer drugs) or a novel indication. For example, IGF1R is targeted by 163 recombinant insulin growth factor 1 Mecasermin for growth failure in children 164 (marketed agonist drug) and is evaluated as target for treatment of solid tumours 165 (antagonist drug PL-225B in phase 1 trial NCT01779336). 431 of all 691 targets, 166 62.4% (Fig. 3a) and only 24 of 70 tissue-specific targets, 34.3% (Fig. 3b) were reused 167 in clinical trials. Thus, tissue-specific genes were 'recycled' 1.8 times less frequently 168 than drug targets overall (Fisher test p-value 5.6*10 -6 ). Furthermore, tissue-specific 169 genes represented an older subset of drug targets (Fig. 3c) , although the difference 170 was not statistically significant.
In summary, tissue-specific genes, satisfying x = 6, were 1.8 times more likely to 172 become targets of marketed drug than all protein-coding genes. However, they were 173 not actively explored in phase 1 and 2 clinical trials. We investigated possible 174 explanations for these trends. 175 Disease indication as a confounding factor 176 Targets for oncology drugs are selected following different paradigms than targets for 177 non-oncology drugs. For example, traditional cytotoxic agents aim to induce cell death 178 or inhibit growths through core cell processes, that are carried out by ubiquitously 179 expressed targets like DNA topoisomerase II (etoposide). Oncology drugs have 180 different safety profiles from non-oncology drugs, with more side effects being 181 tolerated. Also, some drugs target cancer-specific mutant proteins, which are not 182 captured by gene expression analysis on healthy tissue. For example, vemurafenib 183 targets mutated BRAF in melanoma according to the FDA label 184 (www.accessdata.fda.gov/drugsatfda_docs/label/2017/202429s012lbl.pdf). 185 Targets of phase 1 drugs were predominantly investigated for oncology indications: 186 253 of 331, 76,4%. Targets of phase 2 drugs displayed an almost balanced 187 representation of targets for oncology -239 of 553, 43.2% -and non-oncology 188 indications -314 of 553, 56.8%. By contrast, most targets of phase 3 drugs -265 of 189 410, 64.6% -and of marketed drugs -479 of 691, 69.3% -were developed for non-190 oncology indications. Prevalence of tissue-specific genes among targets of clinical trial 191 and marketed drugs was confounded by disease indications. 192 Hence, we examined oncology and non-oncology targets separately (Supplementary 193 Fig. 1) . Targets of phase 1 drugs were depleted of tissue-specific genes irrespective 194 of disease indication. The discrepancies between oncology and non-oncology targets 195 started to emerge in phase 2. Targets of marketed non-oncology drugs displayed a 196 2.3-fold overrepresentation in tissue-specific genes (at x = 6: 61 of 479, 12.7% > 1,018 197 of 18,377, 5.5%, Fisher test, p-value 3.6*10 -9 ), which was stronger compared to pooled 198 analysis for all disease indications. By contrast, tissue-specific genes were 199 underrepresented among targets of oncology drugs. 200 Insights from evolutionary biology and population genetics 201 Evolutionary properties may explain the underrepresentation of tissue-specific targets 202 in early clinical trials. Wenhua Lv et al. demonstrated that targets of FDA-approved 203 drugs are more evolutionary conserved than non-target genes 24 . By contrast, in 2004, 204 Winter, Goodstasdt and Ponting investigated expression of 4,960 human genes in 27 205 tissues and demonstrated that tissue-specific genes are less evolutionary conserved 206 than broadly expressed genes using Ka/Ks ratios 17 211 We revisited the analysis with the current larger data set. We examined Ka/Ks ratios 212 for human protein-coding genes and their mouse counterparts because mice are the 213 most common species in preclinical research. We confirmed opposite patterns for mouse orthologs. Conservation of protein sequence is considered a proxy for 222 conservation of biological function 26 . Also, 283 of 1,018 tissue-specific genes (27.8%) 223 compared to 2,719 of all 18,377 protein-coding genes (14.8%) did not have a unique 224 ortholog in mouse. Therefore, absence of a convenient animal model and gaps in 225 translation from animal research to clinical trials in humans may complicate 226 development of tissue-specific genes as drug targets. 227 We next examined selection pressure within the human species using a new metric, 228 that was recently developed by the ExAC consortium -probability of being loss-of-229 function intolerant (pLI) 27 . Genes with high pLI have significantly lower observed than 230 expected frequencies of loss-of-function variants, indicating that deleterious variants 231 in these genes are selected out of the human population. Genes with pLI >= 0.9 are 232 considered loss-of-function intolerant and their "knockout" in humans implies "some 233 non-trivial survival or reproductive disadvantage" 27 . By contrast, genes with pLI <= 0.1 234 are considered loss-of-function tolerant 27 . In our analysis, tissue-specific genes were 235 enriched in loss-of-function tolerant and depleted of intolerant genes compared to all 236 protein-coding genes (Fig. 4b) . By contrast, targets of oncology drugs were enriched 237 in loss-of-function intolerant (highest Bonferroni adjusted p-value 8*10 -13 in phase 3) 238 and depleted of tolerant genes (highest Bonferroni adjusted p-value 3*10 -9 for 239 marketed drugs). Targets of marketed non-oncology drugs had comparable 240 prevalence of loss-of-function tolerant and intolerant genes compared to all protein-241 coding genes. The distributions of pLI confirmed that tissue-specific genes were more 242 likely to become targets for non-oncology drugs. 243 Genes with pLI >= 0.9 are more likely to be detected in genome-wide association 244 studies (GWAS) 27 , and to attract attention as candidate drug targets through GWAS. 245 We investigated whether less conserved tissue-specific genes were less frequently 246 found in GWAS. GWAS variants are often located in intergenic regions and can be 247 mapped to candidate genes by proximity on the chromosome or through an 248 association between genotype of the GWAS variant and expression of a gene (eQTL). 249 Mapping through eQTL can highlight regulatory relationships in disease-relevant 250 tissues 28 , and, consequently, is frequently used. The two types of mapping can 251 highlight different candidate genes 29, 30 , and require follow-up experiments to 252 determine causal genes. Tissue-specific genes were equally likely to be detected as 253 a nearest gene to a GWAS variant but 1.3 times less likely to be mapped from GWAS 254 to single-tissue cis-eQTLs than all protein-coding genes (Fisher test, Bonferroni 255 adjusted p-value 2*10 -9 ). Interestingly, only mapping by proximity on chromosome 256 distinguished drug targets from all protein-coding genes ( Supplementary Fig. 2 ). 111 257 of 392 (28.3%) of GWAS to eQTL relationships for tissue-specific genes were detected 258 in the corresponding tissues with highest expression. These results were not 259 surprising. Our definition of tissue-specificity allowed lower expression in other tissues. 260 Some tissues, including kidney cortex with 48 tissue-specific genes, had no eQTL data 261 due to insufficiently high number of samples and did not contribute to this analysis. 262 Also, approximately a third of GWAS to eQTL relationships can only be captured using 263 multiple tissues, while single-tissue analyses lack power to detect the associations 30 . 264 Thus, tissue-specific genes were less likely to be highlighted as candidate targets if 265 investigators relied on the GWAS to eQTL approach. 266 In summary, underrepresentation of tissue-specific targets in early clinical trials could 267 be attributed to their primary relevance for non-oncology diseases and translational 268 challenges. Despite these challenges, tissue-specific genes were enriched among 269 targets of marketed drugs. We hypothesized that tissue-specificity was related to 270 efficacy and not only to safety.
271
Tissue-specificity vs efficacy 272 Efficacy of a drug can be viewed as a combination of properties of the drug (e.g., 273 potency, bioavailability, selectivity etc.) and properties of its intended target(s). Here, 274 we focus on efficacy-related properties of the targets.
275
Prevalence of disease genes 276 Drugs, that modulate targets with genetic evidence for a human disease, are less likely 277 to fail in clinical trials for lack of efficacy 19 . Knowledge of human genetics can help to 278 understand the biological function of the target, find target engagement biomarkers for 279 clinical trials and estimate dose-response curves 31 . These factors can enhance the 280 chances of a drug to succeed. 281 We compared the prevalence of OMIM 32 and Protein Truncating Variants escaping 282 nonsense mediated decay (PTVesc) genes 33 among tissue-specific genes and drug 283 targets. OMIM genes have an entry in the Online Mendelian Inheritance in Man® 284 Morbid Map data base 32 , are well-known disease genes and are likely to be explored 285 in target discovery. By constrast, PTVesc genes are an emerging class of candidate 286 genes that can cause disease by gain-of-function mechanism. PTVesc genes are 287 significantly depleted of genetic variants, that result in mRNA that escape nonsense-288 mediated decay and production of truncated proteins with altered function (e.g.,
289
PNPLA3 and APOL1) 33 . Methods for detection of PTVesc are recently developed, so 290 PTVesc genes are unlikely to be explored to the same extend as OMIM genes. Tissue-291 specific genes were enriched in both OMIM and PTVesc genes (Fig. 5) . The outcomes 292 of Fisher exact test for tissue-specific genes were 272 of 1,018 > 3,870 of 18,377, 293 Bonferroni adjusted p-value 2*10 -4 for OMIM genes and 159 of 1,018 > 1,913 of 294 18,377, Bonferroni adjusted p-value 4*10 -6 for PTVesc genes. As expected, drug 295 targets for oncology and non-oncology indications across all phases of clinical 296 development were enriched only in OMIM genes ( Fig. 5a) . By contrast, the prevalence 297 of PTVesc genes among drug targets did not significantly deviate from the overall 298 prevalence among protein-coding genes ( Fig. 5b) . 299 In total, 386 of 1,018 tissue-specific genes (37.9%) were OMIM genes or PTVesc 300 genes or both. Thus, tissue-specific genes were more likely to provide necessary 301 information for development of efficacious drugs through human genetics than protein-302 coding genes overall.
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Network analysis 304 The ability to spread perturbations through the cell and cause phenotypic changes is 305 a key property of drug targets, which is reflected by topological properties in protein- 306 protein interaction (PPI) networks 34 . We explain the network topology properties in 307 Supplementary Fig. 3 . We recommend section 2 in 35 for a detailed explanation of the 308 relationship between network topology properties and spread of perturbations. 309 We performed network analysis on STRING v10.5 36 (Supplementary Data 2) 310 because tissue-specific proteins are well represented in this data base 37 . We included 311 three gene sets with known ability to affect phenotype as controls. Distribution of 312 network-topological properties of these genes should indicate if the PPI network 313 accurately reflects the ability of genes to spread perturbations and cause phenotype. 314 Essential genes cause cell death or hamper growth upon silencing in two human 315 cancer cell lines 38 . These genes serve as positive control for severe phenotypes. 316 OMIM genes cause disease and serve as positive control for less severe phenotypes. 317 Genes with rare homozygous loss-of-function rhLOF variants in three human cohorts 318 serve as negative no-phenotype controls (British-Pakistani, ExAC and Icelandic 319 individuals, Suppl. Table 2 from 39 ). The human subjects come from the general 320 population and are assumed to be healthy, so loss of function of rhLOF genes is 321 assumed to be compensated. No association between presence of rhLOF genes and 322 rate of drug prescriptions and medical consultations has been confirmed in the British-323 Pakistani cohort 39 . 324 First, we investigated the sources of supporting evidence for PPIs (Supplementary 325 Fig. 4) . Tissue-specific genes did not markedly differ from all protein-coding genes in 326 this respect. Each PPI had a score reflecting the amount of cumulative evidence 327 supporting existence of the interaction. Interestingly, non-oncology drug targets from 328 phase 1 to the market tended to have more high confidence PPIs than other gene 329 categories (a). PPIs for oncology drug targets and essential genes had more support 330 from co-expression across multiple experiments and tissues (f) and the experimental 331 evidence channel (g). PPIs of non-oncology drug targets tended to have more support 332 from pathway data bases (h). We concluded that indirect (functional) interactions were analysis. The neighbourhood (c), fusion (d) and co-occurrence (e) channels provided 338 support for relatively few PPIs, consistent with primary relevance of these three 339 evidence channels for PPIs in Archaea and Bacteria 36 . 340 We observed that most PPIs had low confidence scores even for drug targets (b). 341 Mora and Donaldson demonstrated that removing low confidence interaction does not 342 substantially improve the ability to discriminate drug targets based on their topological 343 properties 40 . Hence, we analysed the complete interaction set, but directly 344 incorporated the confidence in PPIs into the calculations and computed weighted 345 topological properties (see Methods/Network analysis for details). The calculations were performed on the largest connected component including 19,574 proteins and 347 5,676,527 PPIs. The network diameter (unweighted) was 6. Topological properties of 348 the nodes accurately reflected their ability to spread perturbations through the network 349 ( Fig. 6 and Table 1 ). Distributions of centrality scores among rhLOF genes did not 350 significantly differ from the overall distributions among protein-coding genes (except 351 for slightly lower closeness centrality scores). Drug targets, OMIM genes and essential 352 genes had elevated centrality scores. Betweenness centrality was the only topological 353 property that could distinguish tissue-specific genes from all protein-coding genes 354 ( Table 1) . The trend was nominally significant but did not pass the correction for 355 multiple testing. Our results were consistent with the previous study on regulatory 356 networks, in which the Sonawane et al. applied a less stringent definition of tissue-357 specificity and found that tissue-specific genes serve as "bottlenecks" on signaling 358 paths 41 . 359 We further investigated which tissue-specific genes had high betweenness centrality 360 scores. The ten highest betweenness centrality scores were for genes encoding 361 hormones (insulin INS; glucagon GCG; POMC giving rise to adrenocorticotrophin and 362 lipotropin beta in the pituitary), other secreted proteins (albumin ALB; neuropeptide S 363 NPS; plasminogen PLG; APOA1, a major constituent of high density lipoprotein 364 cholesterol), rate limiting enzyme in synthesis of bile acids CYP7A1, mitochondrial 365 enzyme FDXR and electron transporter FDX1 acting together in synthesis of steroid 366 hormones in the adrenal glands. Enzymes and secreted proteins, that were expressed 367 in a tissue-specific manner, had higher betweenness centrality scores than other 368 tissue-specific genes ( Supplementary Table 1 ). These genes may have important 369 functional interactions and their modulation may cause effects outside of their tissue-370 of-origin. For example, aliskiren fumarate inhibits the kidney-specific enzyme renin REN that is part of the renin-angiotensin-aldosterone system, lowers blood pressure 372 and mitigates manifestations of hypertension in the whole body.
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Historic precedents to guide future applications 374 In total, only 100 of 1,018 (9.8%) tissue-specific genes were explored as targets of 375 marketed or clinical trial drugs. 284 of the remaining 918 (30.9%) tissue-specific genes 376 were classified as Tdark in the TCRD data base 42 , i.e., were poorly researched with 377 unknown biological function. 529 of 918 (57.6%) showed some indication of 378 druggability by small molecule or antibody approaches ( Supplementary Fig. 5 ). The 379 definition of druggability constantly expands, and targets that cannot be modulated 380 with small molecules or antibodies may be targeted by antisense oligonucleotides or 381 other approaches. Hence, the opportunities to identify novel drug targets among 382 tissue-specific genes were not exhausted. In the next subsections, we review how 383 tissue-specific genes have been used historically and highlight promising future 384 applications.
385
Tissue-specific drug targets 386 Tissue-specific genes are targeted by drugs approved for diverse disease indications 387 ( Table 2) . Tissue-specific genes can be targeted by small molecules (e.g., ACE -388 captopril), analogues of endogenous substances (AVPR1Bdesmopressin acetate, 389 an analogue of vasopressin), antibodies (TNF -etanercept) and new modalities. We 390 and other researchers 9,17 demonstrated that tissue-specific genes are enriched in 391 OMIM genes. Hence, defective forms of tissue-specific genes causing rare monogenic 392 diseases are potential targets for genome editing with the emerging CRISPR/Cas9 393 technology (e.g., surfactant genes in surfactant deficiencies 43 , SERPINA1 in alpha-1 394 antitrypsin deficiency 44 ). Historically, tissue-specific genes were predominantly targets for non-oncology 396 diseases. However, tissue-specific genes also find applications in oncology (e.g., 397 mitotane for endocrine therapy in inoperable adrenocortical carcinoma 45 ) and as 398 targets for pharmacoenhancers. These application scenarios may be expanded in the 399 future. 400 The pharmacoenhancer Cobicistat is administered together with antiretroviral drugs 401 and inhibits cytochromes of CYP3A subfamily that degrade antiretroviral drugs 402 primarily in the liver and intestines. Cobicistat helps to maintain therapeutic 403 concentration of antiretroviral agents for a longer time whereby improving adherence 404 to therapy in HIV patients 46 . Drug-metabolizing enzymes such as the liver-specific 405 cytochromes CYP1A2, CYP2D6 and CYP2C9 47 may be candidate targets for other 406 pharmcoenhancers to improve bioavailability or prolong action of the main drug. 407 Tissue-specific genes represent potential targets for antibody-based therapies (e.g., 408 mammary gland specific transcription factor ANKRD30A for breast cancer 48 ). 409 Promoters of tissue-specific genes can be used in oncolytic viral therapies to achieve 410 specific expression of the virus in the target tissue (e.g., urothelium-specific 411 adenovirus CG8840 with uroplakin 2 UPK2 promoter for bladder cancer 49 and 412 prostate-specific antigen KLK3 targeted adenovirus CG7870 for prostate cancer 50 ). N-413 acetylgalactosamine (GalNAc)-conjugated antisense oligonucleotide drugs bind to the 414 liver-specific ASGR1 and enable targeted delivery to hepatocytes 51 . Similarly, tissue-415 specific genes can be explored as targets for other targeted delivery approaches, and 416 not only in cancer. Non-coding genes 455 We focused on protein-coding genes, but long non-coding RNA (lncRNA) also tend to 456 be expressed in tissue-and cell-type specific manner 60 . We identified 2,113 long non-457 coding RNAs (Supplementary Data 3) , from which 77 were tissue-specific at x = 6 458 and confirmed polyadenylated, i.e., reliably detected with the GTEx RNA sequencing Theoretically, overrepresentation of tissue-specific targets on the market and 467 depletion in phase 1 could reflect a historic shift in target selection paradigms. 468 However, Rouillard and colleagues 20 studied phase 3 drugs (projects with comparable 469 "age") and demonstrated that drugs modulating tissue-specific targets are more likely to succeed in phase 3 and gain regulatory approval. Thus, the data presented in Fig.   471 2 and Supplementary Fig. 1 do not merely represent a historic trend. We are justified 472 to state that drugs modulating tissue-specific targets are indeed more likely to progress 473 in the clinic. We observed that tissue-specific genes, satisfying x = 6, were 1.8 times 474 more likely to become targets of marketed drugs and 2.3 times more likely to become 475 targets of marketed non-oncology drugs than protein-coding genes overall. Our 476 findings were consistent with the previous studies 8,9 . 477 Success of tissue-specific genes as drug targets may be due to a complex 478 combination of factors. Good understanding of target biology is essential for target- 559 We applied Fisher exact test for count data because sample sizes were small in some 560 instances (e.g., 3 tissue-specific targets in phase 1 at x = 6) and to be consistent in 561 other analyses. Mann-Whitney U test was used to test differences between groups forFig. 4 . Tissue-specific genes were subject to less strong selection pressure compared to all protein-coding genes and drug targets. a Ka/Ks ratios for human-mouse 1:1 orthologs. 1:1 ortholog refers to a human gene with one unique counterpart in mouse as opposed to 1-to-many or many-to-many orthologs that arise from duplication or gene fusion events. b Percentages of loss-of-function intolerant (ExAC consortium pLI ≥ 0.9) and tolerant (pLI ≤ 0.1) genes among tissue-specific genes and drug targets compared to all protein-coding genes. Discrepancies in sample size are due to different numbers of genes mapped to the respective data sets. Fig. 5 . Tissue-specific genes were enriched in disease genes and potential disease genes with gain-offunction mechanism. The bars show percentages of a OMIM and b PTVesc genes in each gene category.
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